JP2022528324A5 - - Google Patents
Info
- Publication number
- JP2022528324A5 JP2022528324A5 JP2021556845A JP2021556845A JP2022528324A5 JP 2022528324 A5 JP2022528324 A5 JP 2022528324A5 JP 2021556845 A JP2021556845 A JP 2021556845A JP 2021556845 A JP2021556845 A JP 2021556845A JP 2022528324 A5 JP2022528324 A5 JP 2022528324A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201902713S | 2019-03-26 | ||
| SG10201902713S | 2019-03-26 | ||
| SG10201905063R | 2019-06-03 | ||
| SG10201905063R | 2019-06-03 | ||
| SG10201907597W | 2019-08-16 | ||
| SG10201907597W | 2019-08-16 | ||
| PCT/SG2020/050170 WO2020197502A1 (en) | 2019-03-26 | 2020-03-26 | Treatment employing anti-il-13r antibody or binding fragment thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022528324A JP2022528324A (ja) | 2022-06-10 |
| JP2022528324A5 true JP2022528324A5 (https=) | 2023-04-05 |
Family
ID=70228774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556845A Pending JP2022528324A (ja) | 2019-03-26 | 2020-03-26 | 抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210277131A1 (https=) |
| EP (1) | EP3947457A1 (https=) |
| JP (1) | JP2022528324A (https=) |
| KR (1) | KR20210143788A (https=) |
| CN (1) | CN113677708A (https=) |
| AU (1) | AU2020247175A1 (https=) |
| CA (1) | CA3134495A1 (https=) |
| IL (1) | IL286603A (https=) |
| SG (1) | SG11202109545VA (https=) |
| WO (1) | WO2020197502A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
| AU2022231628A1 (en) * | 2021-03-01 | 2023-09-07 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
| WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| AU2022229076A1 (en) * | 2021-03-01 | 2023-09-07 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| WO2023048651A1 (en) * | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
| WO2023048650A1 (en) * | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
| WO2023075702A1 (en) * | 2021-10-29 | 2023-05-04 | Aslan Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
| EP4422684A1 (en) * | 2021-10-29 | 2024-09-04 | ASLAN Pharmaceuticals Pte Ltd | Anti-il-13r antibody formulation |
| TW202337905A (zh) * | 2022-02-23 | 2023-10-01 | 新加坡商亞獅康私人有限公司 | 抗il13r抗體之糖基化形式 |
| EP4590335A1 (en) * | 2022-08-26 | 2025-07-30 | ASLAN Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
| WO2025095864A1 (en) * | 2023-11-02 | 2025-05-08 | Aslan Pharmaceuticals Pte Ltd | Treatment |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| JP4224135B2 (ja) | 1995-10-23 | 2009-02-12 | ズィナイス セラピューティックス ピーティーワイ．エルティーディー． | 新規なヘモポエチン受容体およびそれをコードする遺伝子配列 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| EP1449851A4 (en) | 2001-11-27 | 2005-11-16 | Mochida Pharm Co Ltd | NEUTRALIZING ANTIBODIES OF IL13 ALPHA RECEPTOR 1 |
| CA2480059C (en) | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| PL2829551T3 (pl) * | 2006-10-19 | 2018-04-30 | Csl Limited | Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13 |
| AU2007319605B2 (en) * | 2006-10-19 | 2011-02-17 | Csl Limited | Anti-IL-13R alpha 1 antibodies and their uses thereof |
| AR066240A1 (es) * | 2007-04-23 | 2009-08-05 | Wyeth Corp | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| EP2458990B1 (en) * | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| WO2016109822A1 (en) * | 2014-12-31 | 2016-07-07 | Novelmed Therapeutics, Inc. | Formulation of aglycosylated therapeutic antibodies |
| US20200165347A1 (en) * | 2017-06-30 | 2020-05-28 | Aslan Pharmaceuticals Pte Ltd | Method of treatment using il-13r antibody |
-
2020
- 2020-03-26 CN CN202080022235.4A patent/CN113677708A/zh active Pending
- 2020-03-26 EP EP20717992.0A patent/EP3947457A1/en active Pending
- 2020-03-26 CA CA3134495A patent/CA3134495A1/en active Pending
- 2020-03-26 SG SG11202109545V patent/SG11202109545VA/en unknown
- 2020-03-26 WO PCT/SG2020/050170 patent/WO2020197502A1/en not_active Ceased
- 2020-03-26 KR KR1020217032020A patent/KR20210143788A/ko active Pending
- 2020-03-26 AU AU2020247175A patent/AU2020247175A1/en active Pending
- 2020-03-26 JP JP2021556845A patent/JP2022528324A/ja active Pending
- 2020-03-26 US US17/272,243 patent/US20210277131A1/en active Pending
-
2021
- 2021-09-22 IL IL286603A patent/IL286603A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022528324A5 (https=) | ||
| JP2020505381A5 (https=) | ||
| JP2024156992A (ja) | 関節リウマチの治療 | |
| JP2022120009A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2016512262A (ja) | 血管炎の処置におけるレボセチリジン及びモンテルカストの使用 | |
| JP7832124B2 (ja) | コロナウイルス感染症治療のためのｔｌｒ７／８拮抗薬 | |
| McDermott | Rilonacept in the treatment of chronic inflammatory disorders | |
| JP2023513833A5 (https=) | ||
| JP2022550919A5 (https=) | ||
| AU2015382376B2 (en) | Cenicriviroc for the treatment of fibrosis | |
| CN115605194A (zh) | 过度炎症综合征的治疗 | |
| JP2024546121A5 (https=) | ||
| Markatseli et al. | Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study | |
| RU2006113701A (ru) | Лечение респираторных заболеваний антителами против рецептора il-2 | |
| JP2007506681A5 (https=) | ||
| US20250042985A1 (en) | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp) | |
| JP2022549066A5 (https=) | ||
| JP2023519853A5 (https=) | ||
| US20260008865A1 (en) | Antibodies, compositions, and methods of treatment | |
| CA3173611A1 (en) | Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin | |
| Schreck | Asthma pathophysiology and evidence-based treatment of severe exacerbations | |
| CN111683681A (zh) | 包含抗ox40抗体的制剂、其制备方法及其用途 | |
| TW202423978A (zh) | 急性呼吸衰竭之治療 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| EP3957364A1 (en) | A binding molecule specifically binding to human cd4 for use in the treatment of pulmonary diseases |